Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy.

ABSTRACT:

Background

Guidelines recommend left ventricular ejection fraction (LVEF) assessments every 3 months for cardiotoxicity monitoring during human epidermal growth factor receptor 2 (HER2) targeted therapy. Evidence in support of this practice is lacking.

Objectives

This study examines the association between adherence to cardiotoxicity surveillance guidelines and heart failure (HF) in HER2-positive breast cancer patients.

Methods

A case-control study was performed in 53 patients who developed cardiotoxicity during HER2 targeted therapy, and 159 controls matched by age, anthracycline exposure, and year of treatment. Cardiotoxicity was defined as HF (New York Heart Association functional class III or IV) or cardiac death. Adherence to cardiotoxicity surveillance guideline

SUBMITTER: Yu AF 

PROVIDER: S-EPMC7584138 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature